During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 1.87 million, with the beta value of the company hitting 2.78. At the end of the trading day, the stock’s price was $0.22, reflecting an intraday loss of -4.37% or -$0.01. The company’s market capitalization is $56.31M, and the average intraday trading volume over the past 10 days was 3.33 million shares, and the average trade volume was 1.62 million shares over the past three months.
Adaptimmune Therapeutics Plc ADR (ADAP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.14. ADAP has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Adaptimmune Therapeutics Plc ADR (ADAP) registered a -4.37% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.37% in intraday trading to $0.22, hitting a weekly high. The stock’s 5-day price performance is -21.43%, and it has moved by -62.52% in 30 days. Based on these gigs, the overall price performance for the year is -84.72%. The short interest in Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is 5.64 million shares and it means that shorts have 4.59 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 92.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $4 respectively. As a result, ADAP is trading at a discount of -1718.18% off the target high and -354.55% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 26.53%. While earnings are projected to return -53.33% in 2025.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is due to release its next quarterly earnings on 2025-Mar-23. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Adaptimmune Therapeutics Plc ADR insiders own 0.31% of total outstanding shares while institutional holders control 49.59%, with the float percentage being 49.74%. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the largest shareholder of the company, while 94.0 institutions own stock in it. As of 2024-06-30, the company held over 38.97 million shares (or 2.5415% of all shares), a total value of $38.0 million in shares.
The next largest institutional holding, with 27.4 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 1.787% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $26.72 million.
